Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting

Rhea-AI Summary

Curative Biotechnology (CUBT, temporarily CUBTD) executed a 1-for-150 reverse stock split effective March 23, 2026, reducing outstanding shares from ~1.02 billion to ~6.8 million and DTC-eligible shares from ~266.8 million to ~1.78 million. The company's ticker will show as CUBTD for 20 trading days.

Curative plans manufacturing to begin mid-April 2026, received a U.S. manufacturer proposal for sterile metformin ophthalmic drops, intends a Phase 1 NIH CRADA human study for dry AMD, and will pursue an OTCQB uplisting after a manufacturing agreement.

Positive

• Reverse split 1-for-150 reduces outstanding shares from ~1.02B to ~6.8M
• DTC-eligible shares reduced from ~266.8M to ~1.78M, improving share structure
• Planned manufacturing start in mid-April 2026 with stability testing capability
• Planned Phase 1 human study at NIH under a CRADA for dry AMD
• Company pursuing OTCQB uplisting after executing manufacturing and development agreement

Negative

• Reverse split will dramatically shrink publicly reported share count, potentially reducing trading float
• Temporary ticker change to CUBTD for 20 trading days may cause short-term investor confusion
• Company remains development-stage with no disclosed financial results or revenue figures

Key Figures

Reverse split ratio: 1-for-150 Outstanding shares pre-split: approximately 1.02 billion shares Outstanding shares post-split: approximately 6.8 million shares +5 more

8 metrics

Reverse split ratio 1-for-150 Reverse stock split of common shares effective March 23, 2026

Outstanding shares pre-split approximately 1.02 billion shares Common stock before 1-for-150 reverse split

Outstanding shares post-split approximately 6.8 million shares Common stock after 1-for-150 reverse split

DTC-eligible shares pre-split approximately 266.8 million shares Shares eligible for electronic trading before split

DTC-eligible shares post-split approximately 1.78 million shares Shares eligible for electronic trading after split

Temporary ticker period 20 trading days CUBTD temporary ticker duration following reverse split

Canine PRA trial size approximately 300 dogs Planned effectiveness trial for PRA canine indication

Accelerated CPRA trial size 24 dogs Single accelerated trial for CPRA canine indication mentioned in prior plan

Market Reality Check

Price: $0.0068 Vol: Volume 245,105 vs 20-day ...

high vol

$0.0068 Last Close

Volume Volume 245,105 vs 20-day average 721 (relative volume 339.86x) ahead of the reverse split news. high

Technical Shares at 0.0068 were trading below the 200-day MA of 1.22, near the 52-week low.

Peers on Argus

While CUBT was down 13.92%, close peers showed limited movement, with some flat ...

While CUBT was down 13.92%, close peers showed limited movement, with some flat and others modestly higher (e.g., PRVCF +2.13%, ZEOX +5.38%), indicating a stock-specific move.

Historical Context

2 past events · Latest: Jan 23 (Positive)

Pattern 2 events

Date	Event	Sentiment	Move	Catalyst
Jan 23	Patent allowance	Positive	+0.0%	Canadian patent allowance with 22 claims for retinal degeneration delivery approaches.
Nov 18	Strategic update	Positive	+37.1%	Strategic redirection, reverse split plan, and planned OTCQB uplisting announcement.

Pattern Detected

Past strategic communications, including reverse split plans and partnership focus, previously coincided with at least one strong positive price reaction, but patent-related news saw no immediate move.

Recent Company History

In the last few months, Curative highlighted intellectual property and strategic repositioning tied to its metformin-based ophthalmology platform. On Nov 18, 2025, a shareholder letter detailed a sublicensing and manufacturing focus, withdrawal of an S-1, a planned 150-to-1 reverse split, and an intended OTCQB uplisting; the stock moved +37.1% over 24 hours. On Jan 23, 2026, a Canadian patent allowance with 22 claims for retinal degeneration delivery approaches drew a 0% one-day reaction. Today’s implemented reverse split and OTCQB ambitions extend this prior strategy into execution.

Market Pulse Summary

This announcement details a 1-for-150 reverse split that cuts outstanding shares from about 1.02 bil...

Analysis

This announcement details a 1-for-150 reverse split that cuts outstanding shares from about 1.02 billion to 6.8 million, alongside plans to uplist to the OTCQB and advance metformin-based ophthalmology programs. It builds on earlier IP gains and strategic updates focused on dry AMD and canine retinal diseases. Investors may watch for execution on the manufacturing start targeted for mid-April 2026, initiation of the NIH Phase 1 human trial, and progress of the planned canine studies as key validation points.

Key Terms

reverse stock split, otcqb venture market, phase 1, age-related macular degeneration, +1 more

5 terms

reverse stock split financial

"today announced a reverse stock split (“Reverse Stock Split”) of its common stock"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

otcqb venture market financial

"intends to submit an application to uplist its common stock to the OTCQB Venture Market"

The OTCQB Venture Market is a tier of the over‑the‑counter (OTC) trading platform that groups early‑stage, smaller companies that do not meet the stricter requirements of higher OTC tiers. It gives investors a way to buy and sell shares in these higher‑risk, less mature firms with generally lower reporting and transparency standards; think of it as a marketplace’s “starter lane” where potential is available but uncertainty and volatility are higher, so investors should expect greater risk and do extra homework.

phase 1 medical

"producing sterile metformin ophthalmic drops in quantities sufficient to support both an initial Phase 1 human clinical study"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

age-related macular degeneration medical

"for the treatment of dry Age-Related Macular Degeneration (AMD)"

Age-related macular degeneration is an eye condition in older adults where the central part of the retina (the macula) progressively loses function, blurring or erasing the sharp, central vision used for reading, driving, and recognizing faces. Investors care because it creates sustained demand for drugs, medical devices, diagnostics, and care services—think of the macula as the camera’s center; if it fails, the market for treatments and related healthcare products can be large and long-lasting.

retinitis pigmentosa medical

"support for development of metformin-based ophthalmic formulations targeting human Retinitis Pigmentosa"

Retinitis pigmentosa is a group of inherited disorders that slowly damage the light-sensing cells in the retina, causing progressive loss of peripheral and night vision and often leading to legal blindness. It matters to investors because the condition defines a clear patient population and long-term need for treatments, making clinical trial design, potential market size, and regulatory approval pathways central considerations when valuing companies developing diagnostics or therapies.

AI-generated analysis. Not financial advice.

Strengthening Capital Structure and Advancing Clinical Development Strategy

Palm Beach Gardens, FL, March 23, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBTD) (“Curative” or the “Company”), a development-stage biomedical company focused on novel treatments for degenerative eye diseases, today announced a reverse stock split (“Reverse Stock Split”) of its common stock at a ratio of 1-for-150. The Reverse Stock Split became effective at 12:00 a.m. Eastern Time on March 23, 2026, and the Company’s common stock is expected to begin trading on a split-adjusted basis at market open on that date. The Company’s ticker symbol on the OTCID quotation system will temporarily change to CUBTD for a period of 20 trading days, including the effective date.

The 1-for-150 Reverse Stock Split will proportionally reduce the number of outstanding shares of the Company’s common stock from approximately 1.02 billion shares to approximately 6.8 million shares. The ownership percentage of each shareholder will remain unchanged, except for minor adjustments related to fractional shares. Proportional adjustments will also be made to the number of shares of common stock issuable upon exercise or conversion of the Company’s outstanding equity awards and warrants, as well as the applicable exercise prices.

Shares held through the Depository Trust Company (DTC) will also be proportionally reduced from approximately 266.8 million shares to approximately 1.78 million shares. These shares represent the portion of the Company’s outstanding stock currently eligible for electronic trading in the public market.

As outlined in the Company’s November 18, 2025 shareholder update, Curative continues to advance development of its metformin-based ophthalmology platform and is pursuing a manufacturing and product development agreement related to this program. The Company has received a proposal from a U.S.-based manufacturer capable of producing sterile metformin ophthalmic drops in quantities sufficient to support both an initial Phase 1 human clinical study and an initial clinical K9 study.

The planned first-in-human clinical study is expected to be conducted at the National Institutes of Health (NIH) under the Company’s Cooperative Research and Development Agreement (CRADA) for the treatment of dry Age-Related Macular Degeneration (AMD).

The Company’s initial K9 target indication is PDE6-associated retinal degeneration, a genetic early-onset retinal disease in dogs. This indication may qualify for the Center for Veterinary Medicine’s (CVM) conditional approval pathway, which permits commercialization for up to five years following demonstration of reasonable expectation of effectiveness, while additional confirmatory data is generated.

A successful K9 study in PDE6-associated retinal degeneration may also provide translational support for development of metformin-based ophthalmic formulations targeting human Retinitis Pigmentosa.

Manufacturing is anticipated to begin in mid-April 2026, and the selected facility is capable of performing required stability testing.

Curative has engaged DSI InPharmatics, a regulatory consulting firm with experience in animal health programs, to assist in development of the clinical protocol for the planned K9 study.

“Consistent with the strategic direction outlined in our November shareholder update, we continue to advance our metformin-based ophthalmology platform toward clinical development,” said Paul Michaels, Executive Chairman of Curative Biotechnology. “The reverse stock split represents an important step in positioning the Company for improved capital structure and broader investor awareness as we continue building the foundation necessary to support upcoming clinical milestones.”

The Company believes that recent strategic and operational progress may increase awareness of Curative’s development programs among a broader range of investors, including institutional investors focused on emerging biotechnology opportunities. Management continues to evaluate potential strategic relationships that could support advancement of its clinical development objectives.

Following execution of the anticipated manufacturing and product development agreement, the Company intends to submit an application to uplist its common stock to the OTCQB Venture Market. The OTCQB market tier is designed for developing companies that meet higher financial reporting standards and corporate governance requirements and may provide improved transparency and credibility with a broader range of market participants.

Future Curative Biotechnology Press Releases and Updates

Interested shareholders and investors may request notification of future press releases and corporate updates by emailing ir@curativebiotech.com.

About Curative Biotechnology, Inc.

Curative Biotechnology, Inc. is a development-stage biomedical company focused on novel therapeutic approaches for rare diseases. The Company is identifying, acquiring, and developing disease-modifying therapeutic drug candidates with an emphasis on rare disease indications. Curative currently maintains programs in degenerative eye disease, infectious disease, and neuro-oncology.

The Company’s primary focus is its degenerative eye disease platform, supported by a worldwide exclusive license from the National Eye Institute (NEI) at the National Institutes of Health (NIH). Its initial human therapeutic candidate is a metformin-based eye drop intended for the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD). A first-in-human clinical trial is targeted for 2026 under a Cooperative Research and Development Agreement (CRADA) with the NEI. The Company is also pursuing a K9 rare ophthalmic disease, PDE6, an early onset retinal degenerative disease.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include, but are not limited to, statements regarding the reverse stock split, potential uplisting, manufacturing activities, sublicense agreements, clinical development plans, and potential therapeutic applications. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially.

Such risks include, among others, uncertainties related to intellectual property protection, regulatory approvals, clinical development outcomes, availability of capital, reliance on third-party collaborators, market acceptance, and the Company’s ability to execute its business strategy.

Readers are encouraged to review the Company’s disclosures filed with OTC Markets for a more complete discussion of risk factors. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact

Paul Michaels
Executive Chairman
Direct: 917-492-8855

Investor Relations
Curative Biotechnology, Inc. (CUBT)
ir@curativebiotech.com

FAQ

What are the details of Curative Biotechnology's 1-for-150 reverse stock split (CUBT) on March 23, 2026?

The reverse split is a 1-for-150 consolidation effective March 23, 2026. According to the company, it reduces outstanding shares from ~1.02 billion to ~6.8 million and adjusts equity awards, warrants and DTC-held shares proportionally.

How will the reverse split affect shareholders of CUBT and fractional shares?

Shareholder ownership percentages remain unchanged except for fractional adjustments. According to the company, proportions are preserved and fractional shares will be handled per the company's established procedures.

When will Curative (CUBT) begin manufacturing its metformin ophthalmic drops and who will produce them?

Manufacturing is anticipated to begin in mid-April 2026. According to the company, a U.S.-based manufacturer has proposed producing sterile metformin ophthalmic drops with capacity for initial human and K9 studies.

What is Curative's planned clinical pathway for metformin ophthalmic drops including the NIH study (CUBT)?

The company plans a first-in-human Phase 1 study at the NIH under a CRADA for dry AMD. According to the company, this follows manufacturing arrangements and precedes additional clinical development steps.

What is the purpose and timeline for Curative's initial K9 study and CVM conditional approval pathway?

The initial K9 study targets PDE6-associated retinal degeneration in dogs and may qualify for CVM conditional approval. According to the company, this pathway can permit up to five years of commercialization while confirmatory data are generated.

When does Curative expect to apply to uplist CUBT to the OTCQB Venture Market?

Curative intends to submit an OTCQB uplisting application after executing the anticipated manufacturing and product development agreement. According to the company, the uplisting follows completion of that commercial agreement.